Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

Proviso in highway bill stalls pollution curbs

Article Abstract:

Congress has added a change to the highway bill expected to be soon signed by President Clinton which puts off attempts to clear air pollution from major national parks and wilderness areas. Without the changes individual states would soon face Environmental Protection Agency requirements to develop plans to develop better air visibility. The move is expected to most benefit the electric utility industry, particularly coal-fired units on the eastern coast which are responsible for much of the air pollution found in some national parks.

Comment:

Utilities get break from Congress by delaying clean air rules for states

Author: Cushman, John H., Jr.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
Government regulation (cont), Fossil Fuel Electric Power Generation, Coal Thermal Electric Power, Coal fired power plants

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Internet is new pet issue in Congress

Article Abstract:

The Internet has become a politically-attractive topic for many legislators in Washington as it grows in influence for a wide range of issues. The Internet influences such areas as commerce, national security, and crime. It is considered to be just as important among lawmakers as are taxes and education. There is a hearing in the US Congress almost every week on an issue relevant to the Internet. Legislators have also been making numerous speeches about cyberspace.

Comment:

Internet becoming a politically-attractive topic for legislators as it grows in influence on a wide range of issues

Author: Alvarez, Lizette
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
On-Line Information Services, Government regulation, Videotex & Teletext, Internet services

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


F.D.A. approves wider use of liver drug; treatment with Rebetron will no longer require interferon first

Article Abstract:

Schering-Plough Corp.'s drug for the treatment of hepatitis C, Rebetron, has received approval to be used 'unbundled' from the company's brand of interferon. The change in use is being allowed due to patient advocates' objections and protest. Original approval was obtained in June 1998. The drug, that is not a cure, costs $6,400 to $8,600 for treatment for 6 months. The drug can have serious side effects in some patients.

Author: Grady, Denise
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
Marketing procedures, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Antiinfective Preparations NEC, Care and treatment, Drugs, Pharmaceutical industry, Marketing, Complications and side effects, Anti-infective agents, Abstract, Hepatitis C, Schering-Plough Corp., SGP, Adverse drug reactions

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Article
Similar abstracts:
  • Abstracts: Redefined maturity spells youthful vigor. It is never to late to be an entrepreneur. The six-stage route to company maturity
  • Abstracts: Information highway maps speed traps. Transfer of records to CD's takes as much labor as love. Musicians tap rich lode of sheet music, sold and shared
  • Abstracts: IRS attacks advertising deductions. Environmental cleanup costs and deductions. Court of Appeals allows current deduction of takeover defense expenses
  • Abstracts: Evolution from quality management to an integrative system in modern business
  • Abstracts: A new role for the Post Office: an investigation into issues behind strategic change at Royal Mail. Editorial: management innovation in public services
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.